| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 627.63 | 2.7% |
| Total Income | 631.03 | 2.8% |
| Expenditure | 499.97 | 0.9% |
| PBT | 131.06 | 14.6% |
| Net Profit | 86.89 | 16.1% |
| OPM | 27.62% | 9.51pp |
| NPM | 13.77% | 2.18pp |
| EPS | 20.14 | 16.9% |
Epigral's Q4FY25 PAT up 13% to Rs 87 Crore; Total Dividend for FY2025 aggregate to Rs 6 per equity share
05 May 2025 · 5 May 2025, 08:22 pm
Summary
Epigral Ltd, a leading integrated chemical manufacturer, announced its financial results for the quarter ended March 31, 2025. The company posted a 13% rise in PAT at Rs 87 crore for Q4FY25. Total revenue stood at Rs 631 crore, a jump of 20% compared to Q4FY24. The company's balance sheet got further strengthened in FY2025 with ROCE at 25% and Net Debt/EBITDA at 0.7x. Epigral's board proposed a final dividend of Rs 3.5 per share, taking the total dividend for FY2025 to Rs 6 per share.
Key Highlights
- 1
Epigral's Q4FY25 PAT up 13% to Rs 87 Crore
- 2
Total Dividend for FY2025 aggregate to Rs 6 per equity share (60% of FV Rs 10)
- 3
Epigral's credit rating upgraded to Crisil AA from Crisil AA-
- 4
Epigral spent Rs 195 Crore on capex in FY2025
- 5
Epigral’s board has approved doubling its CPVC Resin and Epichlorohydrin (ECH) Capacity
Management Comments
Maulik Patel
We ended FY2025 with the highest ever revenue of Rs. 2,565 Cr a growth of 33% compared to previous year. This growth is on account of volume rise of 11%, majorly from high value products. Derivatives & Specialty business volume grew by around 24% in FY2025 and its contribution to revenue touched 54% compared to 45% in FY24. Considering the growth opportunity, we further announced expanding our CPVC and Epichlorohydrin capacity which are expected to commission in 1° half of FY2027 and will contribute from FY2027 onwards. Our integrated complex will further strengthen, once these projects reach optimum utilization. We are geared up and strengthened our position, to grow further, by focusing on import substitute products, further diversifying and increasing Derivatives & Specialty business and with prudence allocation of capital, rewarding our stakeholders.
Informational and educational content only. Not investment advice.